Musk v. Altman: Closing arguments end, jury to deliberate Monday

Closing arguments concluded Thursday in the high-profile Musk v. Altman trial, setting the stage for a nine-person jury to begin advisory deliberations on Monday. The court has emphasized that the jury’s verdict will be non-binding, leaving the ultimate decision and any remedies to the presiding judge.

Throughout the weeks of testimony, plaintiffs and defendants presented competing narratives: Elon Musk alleges that OpenAI and CEO Sam Altman breached the nonprofit’s founding mission by effectively converting it into a for-profit vehicle and enriching executives, while OpenAI and Microsoft countered with documentary evidence and witness testimony justifying corporate decisions and partnership terms. Judge Yvonne Gonzalez Rogers has signaled that statute-of-limitations issues and legal standards could allow her to override or narrow any advisory findings.

From a market perspective, the trial does not directly affect a listed OpenAI equity, but the involvement of major public companies—most notably Microsoft—creates channels for investor sentiment to move related technology and AI-focused stocks. Analysts note that reputational risk and uncertainty around potential damages can exacerbate short-term volatility in the sector, especially amid broader macro and rate-driven investor re-pricing.

The case carries broader implications for governance of AI research organizations, the nexus between nonprofit missions and commercial partnerships, and regulatory scrutiny of rapid AI commercialization. The public courtroom exchanges between Musk and Altman have sharpened debate on ethical oversight, corporate structure choices, and the role of large tech firms in shaping the trajectory of advanced AI systems.

Looking ahead, market watchers expect the jury’s advisory finding to be only the first milestone: if the jury signals liability, the court will quickly move to remedies and potential damages, a phase that could materialize later in the week. Ultimately, Judge Gonzalez Rogers’ rulings on legal sufficiency and timing issues will determine whether any advisory verdict translates into enforceable remedies—an outcome that market participants and corporate governance observers will follow closely.